5-(1H-indol-1-yl)-1,3-dimethyl-1H-pyrazole-4-carbaldehyde | 713496-42-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(1H-indol-1-yl)-1,3-dimethyl-1H-pyrazole-4-carbaldehyde
• 英文别名: 5-indol-1-yl-1,3-dimethylpyrazole-4-carbaldehyde
• CAS: 713496-42-5
• 化学式: C₁₄H₁₃N₃O
• 分子量: 239.277
• InChiKey: OCPBEFJZOVAMLU-UHFFFAOYSA-N

物化性质

• 沸点：
  371.8±42.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  39.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(1H-indol-1-yl)-1,3-dimethyl-1H-pyrazole-4-carbaldehyde 在 sodium hydroxide 、 羟胺 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Identification of antitumor activity of pyrazole oxime ethers

  摘要：

  A series of pyrazole oxime ether derivatives were prepared and examined as cytotoxic agents. In particular, 5-phenoxypyrazole was comparable to doxorubicin, while exhibiting very potent cytotoxicity against XF 498 and HCT15. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.082
• 作为产物：
  描述：

  1,3-二甲基-5-吡唑酮 在 三氯氧磷 作用下， 生成 5-(1H-indol-1-yl)-1,3-dimethyl-1H-pyrazole-4-carbaldehyde
  参考文献：
  名称：

  Identification of antitumor activity of pyrazole oxime ethers

  摘要：

  A series of pyrazole oxime ether derivatives were prepared and examined as cytotoxic agents. In particular, 5-phenoxypyrazole was comparable to doxorubicin, while exhibiting very potent cytotoxicity against XF 498 and HCT15. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.082

文献信息

• Fused ring compound
  申请人：Tawaraishi Taisuke

  公开号：US20080194617A1

  公开（公告）日：2008-08-14

  The present invention provides an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The present invention relates an agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.

  本发明提供了一种用于预防或治疗糖尿病的药剂，具有优越的降血糖作用，并且与较少的副作用（如体重增加等）相关。本发明涉及一种用于预防或治疗糖尿病的药剂，包括由下式表示的化合物：其中每个符号如描述中所定义，或其盐或前药。
• Introduction of <i>N</i>‐Containing Heterocycles into Pyrazole by Nucleophilic Aromatic Substitution
  作者：Min‐Sup Park、Hyun‐Ja Park、Koon Ha Park、Kee‐In Lee

  DOI：10.1081/scc-120030741

  日期：2004.12.31

  Abstract The nucleophilic aromatic substitution on 5‐chloropyrazoles activated by the electron‐withdrawing formyl group offers a useful method to introduce a wide range of N‐containing heterocycles into them. The rate of reaction was greatly affected by the electronic nature of the N‐1 substitution.

  摘要 吸电子甲酰基活化的 5-氯吡唑上的亲核芳香取代为将各种含氮杂环引入其中提供了一种有用的方法。N-1取代的电子性质对反应速率有很大影响。
• FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA
  申请人：Tawaraishi Taisuke

  公开号：US20110009384A1

  公开（公告）日：2011-01-13

  The present invention provides an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The resent invention relates an agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.

  本发明提供了一种用于预防或治疗糖尿病的药剂，具有优越的降血糖作用，且与体重增加等副作用较少相关。本发明涉及一种用于预防或治疗糖尿病的药剂，包括下式所示的化合物：其中每个符号如说明书中所定义，或其盐或前药。
• [EN] FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA<br/>[FR] COMPOSÉS À CYCLES FUSIONNÉS UTILES EN TANT QU'AGONISTES PARTIELS DE PPAR-GAMMA
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2008099794A1

  公开（公告）日：2008-08-21

  [EN] The present invention provides an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The resent invention relates an agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.
  [FR] La présente invention concerne un agent qui est destiné à la prophylaxie ou au traitement du diabète, qui présente un effet hypoglycémique d'un niveau supérieur et qui est associé à des effets secondaires moins nombreux tels qu'une augmentation du poids et autres. Cette invention porte sur un agent utile pour la prophylaxie ou le traitement du diabète qui comprend un composé représenté par la formule (I') dans laquelle chaque symbole est tel que défini dans le descriptif, ou bien un sel ou un promédicament de ce dernier.